Tscan Therapeutics Stock Performance
| TCRX Stock | USD 7.32 0.03 0.41% |
On a scale of 0 to 100, Tscan Therapeutics holds a performance score of 10. The entity has a beta of 0.62, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Tscan Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Tscan Therapeutics is expected to be smaller as well. Please check Tscan Therapeutics' sortino ratio, as well as the relationship between the semi variance and rate of daily change , to make a quick decision on whether Tscan Therapeutics' existing price patterns will revert.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Tscan Therapeutics are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain basic indicators, Tscan Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.41 | Five Day Return 7.33 | Year To Date Return 28.2 | Ten Year Return (30.29) | All Time Return (30.29) |
1 | TScan Therapeutics Releases Quarterly Earnings Results, Beats Expectations By 0.08 EPS | 03/07/2024 |
2 | TScan Therapeutics, Inc. Revenue Breakdown NASDAQTCRX TradingView - TradingView | 03/28/2024 |
3 | TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference | 04/02/2024 |
4 | TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities | 04/16/2024 |
5 | TScan Therapeutics Announces Pricing of Upsized 150 Million Public Offering | 04/17/2024 |
6 | TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting | 04/22/2024 |
7 | TScan Therapeutics Announces Exercise of Underwriters Option to Purchase Additional Shares | 04/24/2024 |
| Begin Period Cash Flow | 120 M |
Tscan |
Tscan Therapeutics Relative Risk vs. Return Landscape
If you would invest 524.00 in Tscan Therapeutics on January 28, 2024 and sell it today you would earn a total of 208.00 from holding Tscan Therapeutics or generate 39.69% return on investment over 90 days. Tscan Therapeutics is currently generating 0.6367% in daily expected returns and assumes 4.6845% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than Tscan, and 88% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Tscan Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tscan Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Tscan Therapeutics, and traders can use it to determine the average amount a Tscan Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1359
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TCRX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.68 actual daily | 41 59% of assets are more volatile |
Expected Return
| 0.64 actual daily | 12 88% of assets have higher returns |
Risk-Adjusted Return
| 0.14 actual daily | 10 90% of assets perform better |
Based on monthly moving average Tscan Therapeutics is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Tscan Therapeutics by adding it to a well-diversified portfolio.
Tscan Therapeutics Fundamentals Growth
Tscan Stock prices reflect investors' perceptions of the future prospects and financial health of Tscan Therapeutics, and Tscan Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tscan Stock performance.
| Return On Equity | -0.71 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (2.96) % | ||||
| Current Valuation | 250.89 M | ||||
| Shares Outstanding | 48.59 M | ||||
| Price To Earning | 23.45 X | ||||
| Price To Book | 2.48 X | ||||
| Price To Sales | 17.64 X | ||||
| Revenue | 21.05 M | ||||
| Gross Profit | (46.28 M) | ||||
| EBITDA | (88.1 M) | ||||
| Net Income | (89.22 M) | ||||
| Cash And Equivalents | 125.6 M | ||||
| Cash Per Share | 5.22 X | ||||
| Total Debt | 92.43 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 7.53 X | ||||
| Book Value Per Share | 3.15 X | ||||
| Cash Flow From Operations | (61.36 M) | ||||
| Earnings Per Share | (1.36) X | ||||
| Market Capitalization | 386.96 M | ||||
| Total Asset | 272.15 M | ||||
| Retained Earnings | (247.6 M) | ||||
| Working Capital | 164.42 M | ||||
About Tscan Therapeutics Performance
To evaluate Tscan Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Tscan Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Tscan Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Tscan Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Tscan's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.00 | 0.00 | |
| Return On Tangible Assets | (0.33) | (0.34) | |
| Return On Capital Employed | (0.39) | (0.40) | |
| Return On Assets | (0.33) | (0.34) | |
| Return On Equity | (0.59) | (0.56) |
Things to note about Tscan Therapeutics performance evaluation
Checking the ongoing alerts about Tscan Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tscan Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tscan Therapeutics appears to be risky and price may revert if volatility continues | |
| Tscan Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 21.05 M. Net Loss for the year was (89.22 M) with loss before overhead, payroll, taxes, and interest of (46.28 M). | |
| Tscan Therapeutics currently holds about 125.6 M in cash with (61.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.22. | |
| Over 79.0% of the company shares are owned by institutional investors | |
| Latest headline from globenewswire.com: TScan Therapeutics Announces Exercise of Underwriters Option to Purchase Additional Shares |
- Analyzing Tscan Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tscan Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Tscan Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tscan Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tscan Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tscan Therapeutics' stock. These opinions can provide insight into Tscan Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tscan Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Tscan Stock please use our How to Invest in Tscan Therapeutics guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for Tscan Stock analysis
When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |
Is Tscan Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tscan Therapeutics. If investors know Tscan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tscan Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.36) | Revenue Per Share 0.321 | Quarterly Revenue Growth 1.33 | Return On Assets (0.25) | Return On Equity (0.71) |
The market value of Tscan Therapeutics is measured differently than its book value, which is the value of Tscan that is recorded on the company's balance sheet. Investors also form their own opinion of Tscan Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Tscan Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tscan Therapeutics' market value can be influenced by many factors that don't directly affect Tscan Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tscan Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tscan Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tscan Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.